John Wrangle to Disease-Free Survival
This is a "connection" page, showing publications John Wrangle has written about Disease-Free Survival.
Connection Strength
0.112
-
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 06 22; 376(25):2415-2426.
Score: 0.034
-
Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016 04; 38 Suppl 1:E1068-74.
Score: 0.031
-
Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg. 2012 Feb; 93(2):405-12.
Score: 0.024
-
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec; 1(7):598-607.
Score: 0.023